Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, Chong SG, MacIsaac S, Assayag D, Johannson KA, Fell CD, Marcoux V, Manganas H, Morisset J, Comes A, Fisher JH, Shapera S, Gershon AS, To T, Wong AW, Sadatsafavi M, Wilcox PG, Halayko AJ, Khalil N, Cox G, Richeldi L, Ryerson CJ, and Kolb M
Background: Progressive fibrosing interstitial lung disease (PF-ILD) is characterised by progressive physiological, symptomatic and/or radiographic worsening. The real-world prevalence and characteristics of PF-ILD remain uncertain., Methods: Patients were enrolled from the Canadian Registry for Pulmonary Fibrosis between 2015 and 2020. PF-ILD was defined as a relative forced vital capacity (FVC) decline ≥10%, death, lung transplantation or any two of: relative FVC decline ≥5% and <10%, worsening respiratory symptoms or worsening fibrosis on computed tomography of the chest, all within 24 months of diagnosis. Time-to-event analysis compared progression between key diagnostic subgroups. Characteristics associated with progression were determined by multivariable regression., Results: Of 2746 patients with fibrotic ILD (mean±sd age 65±12 years; 51% female), 1376 (50%) met PF-ILD criteria in the first 24 months of follow-up. PF-ILD occurred in 427 (59%) patients with idiopathic pulmonary fibrosis (IPF), 125 (58%) with fibrotic hypersensitivity pneumonitis (HP), 281 (51%) with unclassifiable ILD (U-ILD) and 402 (45%) with connective tissue disease-associated ILD (CTD-ILD). Compared with IPF, time to progression was similar in patients with HP (hazard ratio (HR) 0.96, 95% CI 0.79-1.17), but was delayed in patients with U-ILD (HR 0.82, 95% CI 0.71-0.96) and CTD-ILD (HR 0.65, 95% CI 0.56-0.74). Background treatment varied across diagnostic subtypes, with 66% of IPF patients receiving antifibrotic therapy, while immunomodulatory therapy was utilised in 49%, 61% and 37% of patients with CHP, CTD-ILD and U-ILD, respectively. Increasing age, male sex, gastro-oesophageal reflux disease and lower baseline pulmonary function were independently associated with progression., Conclusions: Progression is common in patients with fibrotic ILD, and is similarly prevalent in HP and IPF. Routinely collected variables help identify patients at risk for progression and may guide therapeutic strategies., Competing Interests: Conflict of interest: M.M. Farooqi reports no conflicts of interest relevant to this manuscript. Conflict of interest: A. Dvorkin-Gheva reports no conflicts of interest relevant to this manuscript. Conflict of interest: K. Donohoe reports no conflicts of interest relevant to this manuscript. Conflict of interest: K. Garlick was an employee for the medical department of Boehringer Ingelheim at the time of the preparation of this manuscript. Conflict of interest: C. Scallan reports personal fees from Boehringer Ingelheim. Conflict of interest: S.G. Chong reports no conflicts of interest relevant to this manuscript. Conflict of interest: S. MacIsaac reports no conflicts of interest relevant to this manuscript. Conflict of interest: D. Assayag reports personal fees from Roche and Boehringer Ingelheim. Conflict of interest: K.A. Johannson reports grants from Boehringer Ingelheim, Pulmonary Fibrosis Society of Calgary and University of Calgary School of Medicine; personal fees from Boehringer Ingelheim, Roche, Three Lakes Foundation, Pliant Therapeutics, Theravance and Blade Therapeutics. Conflict of interest: C.D. Fell reports educational grants and research grants from Boehringer Ingelheim, Roche and the Canadian Pulmonary Fibrosis Foundation; personal fees from Roche and Boehringer Ingelheim; Chair of the Boards for the Canadian Pulmonary Fibrosis Foundation. Conflict of interest: V. Marcoux reports grants from Boehringer Ingelheim, AstraZeneca and Roche; personal fees from Boehringer Ingelheim and Roche. Conflict of interest: H. Manganas reports grants from Boehringer Ingelheim and Gilead. Conflict of interest: J. Morisset reports personal fees from Boehringer Ingelheim and Roche. Conflict of interest: A. Comes reports no conflicts of interest relevant to this manuscript. Conflict of interest: J.H. Fisher reports no conflicts of interest relevant to this manuscript. Conflict of interest: S. Shapera reports educational grants and research grants from Boehringer Ingelheim, Roche and the Canadian Pulmonary Fibrosis Foundation; personal fees from AstraZeneca, Boehringer Ingelheim Canada and Hoffman La-Roche Canada; served on the medical advisory board for the Canadian Pulmonary Fibrosis Foundation. Conflict of interest: A.S. Gershon reports a research grant from the Canadian Pulmonary Fibrosis Foundation. Conflict of interest: T. To reports no conflicts of interest relevant to this manuscript. Conflict of interest: A.W. Wong reports personal fees from AstraZeneca and Boehringer Ingelheim. Conflict of interest: M. Sadatsafavi reports grants from Boehringer Ingelheim; personal fees from Boehringer Ingelheim. Conflict of interest: P.G. Wilcox reports personal fees from Boehringer Ingelheim. Conflict of interest: A.J. Halayko reports no conflicts of interest relevant to this manuscript. Conflict of interest: N. Khalil reports no conflicts of interest relevant to this manuscript. Conflict of interest: G. Cox reports personal fees from Boehringer Ingelheim and Roche. Conflict of interest: L. Richeldi reports grants and personal fees from Boehringer Ingelheim; personal fees from Biogen, Sanofi-Aventis, Celgene, RespiVant, CSL Behring, Nitto, Pliant Therapeutics, Cipla, Zambon, Promedior, Boehringer Ingelheim, Roche and Fibrogen. Conflict of interest: C.J. Ryerson reports grants from Boehringer Ingelheim; personal fees from Boehringer Ingelheim, Roche, Pliant Therapeutics, Cipla and Veracyte. Conflict of interest: M. Kolb reports grants from the Canadian Institute for Health Research, Roche, Boehringer Ingelheim, Pieris and Prometic; personal fees from Boehringer Ingelheim, Roche, European Respiratory Journal, Belerophon, United Therapeutics, Nitto Denko, MitoImmune, Pieris, AbbVie, DevPro Biopharma, Horizon, Algernon and CSL Behring. Conflict of interest: N. Hambly reports grants from Roche and Boehringer Ingelheim; personal fees from Roche, Boehringer Ingelheim and Janssen., (Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.)